Skip Navigation


Annals of Oncology Advance Access originally published online on December 16, 2008
Annals of Oncology 2009 20(3):413-424; doi:10.1093/annonc/mdn666
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/3/413    most recent
mdn666v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ruan, J.
Right arrow Articles by Leonard, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruan, J.
Right arrow Articles by Leonard, J. P.
Related Collections
Right arrow 2009 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

reviews

Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma

J. Ruan1,*, K. Hajjar2, S. Rafii3 and J. P. Leonard1

1 Division of Hematology/Oncology, Department of Medicine, Center for Lymphoma and Myeloma
2 Department of Cell and Developmental Biology
3 Department of Genetic Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, USA

* Correspondence to: Dr J. Ruan, Division of Hematology/Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, 1300 York Avenue, Room A-605A, NY 10065, USA. Tel: +1-212-746-2932; Fax: +1-212-746-3844; E-mail: jruan{at}med.cornell.edu

Angiogenesis, the growth of new blood vessels, requires dynamic expansion, assembly and stabilization of vascular endothelial cells in response to proangiogenic stimuli. Antiangiogenic strategies have become an important therapeutic modality for solid tumors. While many aspects of postnatal pathological angiogenesis have been extensively studied in the context of nonhematopoietic neoplasms, the precise role of these processes in lymphoma pathogenesis is under active investigation. Lymphoma growth and progression is potentiated by at least two distinct angiogenic mechanisms: autocrine stimulation of tumor cells via expression of vascular endothelial growth factor (VEGF) and VEGF receptors by lymphoma cells, as well as paracrine influences of proangiogenic tumor microenvironment on both local neovascular transformation and recruitment of circulating bone marrow-derived progenitors. Lymphoma-associated infiltrating host cells including hematopoietic monocytes, T cells and mesenchymal pericytes have increasingly been associated with the pathogenesis and prognosis of lymphoma, in part providing perivascular guidance and support to neoangiogenesis. Collectively, these distinct angiogenic mechanisms appear to be important therapeutic targets in selected non-Hodgkin's lymphoma (NHL) subtypes. Understanding these pathways has led to the introduction of antiangiogenic treatment strategies into the clinic where they are currently under assessment in several ongoing studies of NHL patients.

Key words: angiogenesis, antiangiogenic therapy, microenvironment, non-Hodgkin's lymphoma, VEGF

Received for publication July 1, 2008. Revision received September 5, 2008. Accepted for publication September 9, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
J. A. Burger, P. Ghia, A. Rosenwald, and F. Caligaris-Cappio
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Blood, October 15, 2009; 114(16): 3367 - 3375.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.